KELIX Bio, a subsidiary of Mubadala Investment Company, has completed its acquisition of DiabTec, a biomanufacturing facility previously owned by Julphar, one of the UAE’s largest pharmaceutical ...

Julphar recorded revenues of AED1.31 billion, achieving a 2.7% growth compared to the same period last year and a 4% increase on a constant currency basis. Operating profit before interest, taxes ...

Gulf Pharmaceutical Industries PJSC (Julphar), announced a net profit of AED 40.5 million for 2024, supported by sustainable growth and operational efficiency, reflecting the company’s strong ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...